4.6 Article

Prognostic value of ALDH2 polymorphism for patients with oropharyngeal cancer in a Japanese population

期刊

PLOS ONE
卷 12, 期 12, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0187992

关键词

-

资金

  1. Japan Agency for Medical Research and Development [16ck0106223h001]
  2. [26861379]
  3. [16H0548]
  4. [16H05481]
  5. Grants-in-Aid for Scientific Research [16H05481, 16K20230, 17K11384] Funding Source: KAKEN

向作者/读者索取更多资源

Background Half of Japanese possess a polymorphism of aldehyde dehydrogenase 2(ALDH2), while few white individuals possess this mutation. The purpose of this study was to investigate the possibility of ALDH2 polymorphism as a prognostic factor for oropharyngeal cancer (OPC) among Japanese population. Methods We analyzed 82 Japanese patients with OPC treated between 2006 and 2011. The median observation period was 50 months. P16-staining and ALDH2 polymorphisms were investigated. To examine the frequencies of second primary pharyngeal and esophageal cancers (SPPEC), 37 Japanese patients with OPC treated at Tokyo University Hospital were included for statistical analysis. Results Statistically significant differences were noted in OS among sex, age, N classification, and p16 (p = 0.045, 0.024, 0.020, 0.007, respectively). In addition, OS and DSS rates of the patients with heterozygous ALDH2 tended to be worse than those of the patients with homozygous ALDH2 (p = 0.21, 0.086, respectively). Of note, OS and DSS of the patients with p16-negative OPC and heterozygous ALDH2 was significant poorer than those of the patients with p16-positive OPC (p = 0.002, 0.006, respectively), while there was no significant difference in OS and DSS between patients with p16-positive OPC and patients with p16-negative OPC and homozygous ALDH2. Conclusions ALDH2 polymorphism might be a promising prognostic factor for Japanese patients with p16-negative OPC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial

Naomi Kiyota, Makoto Tahara, Junki Mizusawa, Takeshi Kodaira, Hirofumi Fujii, Tomoko Yamazaki, Hiroki Mitani, Shigemichi Iwae, Yasushi Fujimoto, Yusuke Onozawa, Nobuhiro Hanai, Takenori Ogawa, Hiroki Hara, Nobuya Monden, Eiji Shimura, Shujiro Minami, Takashi Fujii, Kaoru Tanaka, Akihiro Homma, Seiichi Yoshimoto, Nobuhiko Oridate, Koichi Omori, Tsutomu Ueda, Kenji Okami, Ichiro Ota, Kiyoto Shiga, Masashi Sugasawa, Takahiro Asakage, Yuki Saito, Shigeyuki Murono, Yasumasa Nishimura, Kenichi Nakamura, Ryuichi Hayashi

Summary: The study demonstrates that chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin in terms of overall survival for patients with postoperative high-risk locally advanced squamous cell carcinoma of the head and neck. Weekly cisplatin also leads to fewer adverse reactions compared to the 3-weekly regimen.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Medicine, General & Internal

Clinicopathologic Analysis of Sinonasal Inverted Papilloma, with Focus on Human Papillomavirus Infection Status

Munechika Tsumura, Seiichiro Makihara, Asami Nishikori, Yuka Gion, Toshiaki Morito, Shotaro Miyamoto, Tomoyuki Naito, Kensuke Uraguchi, Aiko Oka, Tomoyasu Tachibana, Yorihisa Orita, Shin Kariya, Mitsuhiro Okano, Mizuo Ando, Yasuharu Sato

Summary: This study found that HPV infection, young adulthood, diabetes mellitus, and advanced tumor stage may be associated with the recurrence of sinonasal inverted papilloma.

DIAGNOSTICS (2022)

Article Oncology

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge

Taku Nose, Yohei Funakoshi, Hirotaka Suto, Yoshiaki Nagatani, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Hironobu Minami

Summary: This study investigated the time-dependence of PD-1 occupancy after discontinuation of nivolumab and its relationship with re-challenge efficacy. The results showed that it takes approximately 32.4 to 48.9 weeks to decrease PD-1 occupancy by 50% to 70%. Furthermore, patients with lower PD-1 occupancy at recurrence had better efficacy with re-challenge of nivolumab.

MOLECULAR AND CLINICAL ONCOLOGY (2022)

Editorial Material Medicine, General & Internal

Labyrinthitis ossificans following severe acute otitis media

Kensuke Uraguchi, Shin Kariya, Mizuo Ando

Summary: This article presents a rare case of labyrinthitis ossificans following acute otitis media. The T2-weighted MRI showed decreased signal intensity in the right inner ear, consistent with the clinical presentation.

CLINICAL CASE REPORTS (2022)

Article Oncology

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Robert I. Haddad, Kevin Harrington, Makoto Tahara, Robert L. Ferris, Maura Gillison, Jerome Fayette, Amaury Daste, Piotr Koralewski, Bogdan Zurawski, Miren Taberna, Nabil F. Saba, Milena Mak, Andrzej Kawecki, Gustavo Girotto, Miguel Angel Alvarez Avitia, Caroline Even, Joaquin Gabriel Reinoso Toledo, Alexander Guminski, Urs Muller-Richter, Naomi Kiyota, Mustimbo Roberts, Tariq Aziz Khan, Karen Miller-Moslin, Li Wei, Athanassios Argiris

Summary: In patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), first-line nivolumab plus ipilimumab did not show a significant difference in overall survival compared to the standard treatment. However, there may be some advantages in certain populations, and it has a better safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Endocrinology & Metabolism

Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors

Yasunori Fujita, Fumika Kamitani, Masaaki Yamamoto, Hidenori Fukuoka, Yushi Hirota, Nobuharu Nishiyama, Naho Goda, Yuko Okada, Yuiko Inaba, Hiroki Nakajima, Yukako Kurematsu, Keitaro Kanie, Hiroki Shichi, Shin Urai, Masaki Suzuki, Naoki Yamamoto, Hironori Bando, Genzo Iguchi, Hirotaka Suto, Yohei Funakoshi, Naomi Kiyota, Yutaka Takahashi, Wataru Ogawa

Summary: The combination of hypophysitis and type 1 diabetes mellitus (T1DM) caused by immune checkpoint inhibitors (ICIs) is extremely rare, and its clinical features are unclear. This study analyzed the clinical features of three cases and reviewed previously reported cases with combined hypophysitis and T1DM due to ICIs.

JOURNAL OF THE ENDOCRINE SOCIETY (2023)

Article Oncology

Prognostic Value of Radiomics Analysis of Skeletal Muscle After Radical Irradiation of Esophageal Cancer

Kazuma Iwashita, Hikaru Kubota, Riku Nishioka, Yuki Emoto, Daisuki Kawahara, Takeaki Ishihara, Daisuke Miyawaki, Ikuno Nishibuchi, Yasushi Nagata, Ryohei Sasaki

Summary: This study aimed to construct a prognostic survival model for esophageal cancer patients who underwent radical irradiation using skeletal muscle radiomics. The predictive model constructed by machine learning and LASSO algorithm showed good performance in predicting the survival of esophageal cancer patients, with high accuracy, specificity, sensitivity, and area under the concentration-time curve.

ANTICANCER RESEARCH (2023)

Article Hematology

Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration

Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Wataru Hojo, Hironori Sakai, Sakuya Matsumoto, Marika Watanabe, Akihito Kitao, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Taiji Koyama, Yoshiaki Nagatani, Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Mitsuhiro Ito, Hironobu Minami

Summary: The use of tixagevimab/cilgavimab is an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. However, it can mask the production of anti-spike antibody after vaccination, making it difficult to assess vaccine response. A new quantification method using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab) has been established to assess the response to SARS-CoV-2 vaccination at mRNA level. The fluctuation in matching sequences can be analyzed to evaluate the postvaccine immune response.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Review Otorhinolaryngology

Weekly versus 3-weekly cisplatin along with radiotherapy for locoregionally advanced non-nasopharyngeal head and neck cancers: Is the equipoise in literature addressed yet?

Sataksi Chatterjee, Naomi Kiyota, Richa Vaish, Atul Sharma, Makoto Tahara, Vanita Noronha, Kumar Prabhash, Anil D'Cruz

Summary: Concurrent chemoradiotherapy with 3-weekly cisplatin has been the standard treatment for locoregionally advanced head and neck cancer. However, concerns about toxicity, compliance, and real-world applicability have led to exploration of weekly cisplatin chemoradiotherapy as an alternative. A literature review comparing the two regimens was conducted, highlighting the noninferiority of the weekly regimen in both adjuvant and definitive settings.

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2023)

Article Oncology

Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial

Kazuhiro Kitajima, Junpei Kuyama, Takashi Kawahara, Tsuyoshi Suga, Tomoaki Otani, Shigeyasu Sugawara, Yumiko Kono, Yukihisa Tamaki, Ayumi Seko-Nitta, Yoshinobu Ishiwata, Kimiteru Ito, Akira Toriihara, Shiro Watanabe, Makoto Hosono, Hideaki Miyake, Shingo Yamamoto, Ryohei Sasaki, Mitsuhiro Narita, Koichiro Yamakado

Summary: This retrospective study investigated the efficacy of change in the automated bone scan index (aBSI) as an imaging biomarker for treatment response and survival prediction in mCRPC patients treated with Ra-223. The study analyzed data from 205 Japanese mCRPC patients who received Ra-223 treatment between July 2016 and August 2020. The results showed that changes in aBSI, alkaline phosphatase (ALP), and prostate-specific antigen (PSA) were significant prognostic factors for overall survival in these patients.

CANCERS (2023)

Article Health Care Sciences & Services

Serious Long-Term Effects of Head and Neck Cancer from the Survivors' Point of View

Katherine J. Taylor, Cecilie D. Amdal, Kristin Bjordal, Guro L. Astrup, Bente B. Herlofson, Frederic Duprez, Ricardo R. Gama, Alexandre Jacinto, Eva Hammerlid, Melissa Scricciolo, Femke Jansen, Irma M. Verdonck-de Leeuw, Giuseppe Fanetti, Orlando Guntinas-Lichius, Johanna Inhestern, Tatiana Dragan, Alexander Fabian, Andreas Boehm, Ulrike Woehner, Naomi Kiyota, Maximilian Krueger, Pierluigi Bonomo, Monica Pinto, Sandra Nuyts, Joaquim C. Silva, Carmen Stromberger, Francesco Tramacere, Ayman Bushnak, Pietro Perotti, Michaela Plath, Alberto Paderno, Noa Stempler, Maria Kouri, Susanne Singer

Summary: This study investigated the long-term problems of head and neck cancer survivors. The most frequent problems reported were dry mouth, difficulty swallowing/eating, hoarseness/difficulty speaking, and pain in the head and neck. The use of chemo-radiotherapy compared to surgery alone increased the odds of reporting dry mouth and difficulty swallowing/eating, but decreased the odds of hoarseness/difficulty speaking and pain in the head and neck. Patients diagnosed with UICC stage IV had increased odds of reporting hoarseness/difficulty speaking. Laryngeal cancer survivors had lower odds of reporting dry mouth compared to oropharynx cancer survivors, but higher odds of hoarseness/difficulty speaking.

HEALTHCARE (2023)

Review Oncology

Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy

Hiroto Ishiki, Yuichiro Kikawa, Mitsumi Terada, Junki Mizusawa, Michitaka Honda, Tsuguo Iwatani, Tomonori Mizutani, Keita Mori, Naoki Nakamura, Tempei Miyaji, Takuhiro Yamaguchi, Masahiko Ando, Kenichi Nakamura, Haruhiko Fukuda, Naomi Kiyota

Summary: Assessing patient-reported outcomes and health-related quality of life in cancer clinical trials has become increasingly important due to the promotion of patient and public involvement in cancer treatment development. The Japan Clinical Oncology Group has seen growing demand for such assessments, but standardized methods for analyzing and interpreting the results are still lacking. To address this issue, the Japan Clinical Oncology Group has reorganized its patient-reported outcome/quality of life research committee and revised its research policy to promote the inclusion of patient-reported outcomes in future trials.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2023)

Meeting Abstract Oncology

Tumor immune microenvironment in salivary gland cancer.

Yoshiaki Nagatani, Naomi Kiyota, Yoshinori Imamura, Taiji Koyama, Yohei Funakoshi, Masato Komatsu, Masanori Teshima, Ken-Ichi Nibu, Kazuko Sakai, Kazuto Nishio, Manami Shimomura, Tetsuya Nakatsura, Daiki Ikarashi, Takayuki Nakayama, Shigehisa Kitano, Hironobu Minami

CANCER RESEARCH (2022)

Meeting Abstract Oncology

Tumor immune microenvironment in salivary gland cancer

Yoshiaki Nagatani, Naomi Kiyota, Yoshinori Imamura, Taiji Koyama, Yohei Funakoshi, Masato Komatsu, Masanori Teshima, Ken-Ichi Nibu, Kazuko Sakai, Kazuto Nishio, Manami Shimomura, Tetsuya Nakatsura, Daiki Ikarashi, Takayuki Nakayama, Shigehisa Kitano, Hironobu Minami

CANCER RESEARCH (2022)

Article Materials Science, Biomaterials

In vivo stealthified molecularly imprinted polymer nanogels incorporated with gold nanoparticles for radiation therapy

Yukiya Kitayama, Takuya Yamada, Kentaro Kiguchi, Aoi Yoshida, Shuhei Hayashi, Hiroaki Akasaka, Kazunori Igarashi, Yuya Nishimura, Yu Matsumoto, Ryohei Sasaki, Eri Takano, Hirobumi Sunayama, Toshifumi Takeuchi

Summary: A novel stealth radiation sensitizer based on Au-embedded molecularly imprinted polymer nanogels (Au MIP-NGs) was developed for low-dose X-ray radiation therapy. It showed good affinity and selectivity towards human serum albumin, and improved the efficiency of pancreatic cancer treatment in mouse models.

JOURNAL OF MATERIALS CHEMISTRY B (2022)

暂无数据